New Child Vaccine Schedule: Changes & Implications
As widely expected, and following a recent Presidential memorandum, the Department of Health and Human Services (HHS) issued a memo on January 5, 2026 implementing major changes to the government’s recommended vaccination schedule for children, adding to other changes previously made in 2025.Collectively, these changes reduce the number of vaccines recommended for all children and, in this very way, have critically important implications for childhood immunizations and U.S. public health broadly, especially given the context of already declining childhood vaccination rates and ongoing outbreaks of diseases such as influenza and measles. While states, not the federal government, ultimately determine which vaccines are recommended for children and required for school entry, the federal government has significant influence over vaccine policy and access.This policy brief provides an overview and identifies several implications of these changes.
starting in 2025,changes by HHS to routine vaccine recommendations for children have reduced the number of diseases targeted from 17 to 11 and the number of routine vaccines from 13 to 7 (see Table). Due to changes starting in October of last year, there are now six vaccines no longer recommended for routine use by all children in the United States: rotavirus, COVID-19, influenza, hepatitis A, hepatitis B, and meningococcal vaccines. Rather, some of these vaccines are now recommended for a narrower group of children, based on certain risk criteria or other specific factors, and all six have been moved from the routine category of vaccination to “shared clinical decision making” (SCDM), a process that is “individually based and informed by a decision process between the health care provider and the patient or parent/guardian.” Beyond these changes, while HPV vaccine remains routinely recommended, HHS has reduced the number of recommended doses from two or three (depending on age of initial vaccination) to one.
Insurance coverage for childhood vaccines is not expected to change, although there is one exception. Most insurers are required to cover the Advisory Committee on Immunization Practices (ACIP)/Centers for Disease Control and Prevention (CDC) recommended vaccines at no-cost (including those recommended through SCDM), either due to requirements of the Affordable Care Act or other federal statutes and as such, these changes should not affect coverage, as also stated by HHS officials. Thus, parents wishing to vaccinate their children against diseases no longer recommended for all children but available through SCDM may still do so without having to be concerned about out- of-pocket costs. One potential exception relates to the HPV vaccine: now that the federal government recommends just one dose of HPV (instead of the previously recommended two to three doses), i
HHS Updates Childhood Vaccine Schedule, Shifts to Shared Decision-Making
The Department of Health and Human Services (HHS) announced updates to the recommended childhood immunization schedule on January 10, 2026, moving several vaccines from routine recommendations to a shared clinical decision-making (SCDM) model. This change, prompted by a presidential memorandum, raises concerns about potential declines in vaccination rates and public trust.
The updated schedule now includes six vaccines recommended through SCDM: hepatitis B,human papillomavirus (HPV),influenza,meningococcal ACWY,pneumococcal conjugate,and varicella. This approach requires healthcare providers and parents to discuss the risks and benefits of vaccination before administering these vaccines.
HHS officials cite decreased vaccine uptake and declining public trust as key factors driving the changes.However, experts question whether these adjustments will effectively address these issues, suggesting they could instead lead to fewer vaccinations.Some states may follow suit, loosening school vaccine requirements.
The shift to SCDM could introduce barriers to vaccine access, potentially leading to missed vaccination opportunities. According to a CIDRAP op-ed, this approach weakens vaccine policy. While HHS aims to increase public trust, the impact of the new schedule on trust remains uncertain.
The changes also come amid ongoing scrutiny of vaccine testing and safety monitoring, as reported by the Washington Post, and questions surrounding adverse event reporting systems. Moreover, Politico reports on calls to reexamine liability protections for vaccine manufacturers, potentially leading to further policy changes.